Comparing Heart Pumps for Shock With ECMO
Part of Heart & circulation clinical trials.
This study compares two support devices (Impella vs. IABP) for people with cardiogenic shock who are already on ECMO. It looks at how well the left side of the heart recovers when one of these devices is added.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were in cardiogenic shock (heart too weak to pump enough blood) and treated with ECMO plus either an IABP or an Impella device.
- Your treatment happened between January 1, 2010, and December 31, 2023.
- You were not getting CPR at the moment the ECMO was put in.
- You did not have CPR for more than 30 minutes before the ECMO.
- You do not have a severe brain injury, end-stage heart or organ failure, or a mechanical complication from a heart attack.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study reviews how well people tolerated the Impella heart pump during cardiogenic shock and what complications occurred. It looks at past cases from 2010 to 2022 to help doctors understand the safety of this device.
This trial studies whether putting in a small heart pump early (through the leg) helps people with a heart attack complicated by severe heart weakness (“cardiogenic shock”) compared with standard treatment. It aims to improve survival and recovery by supporting blood flow sooner.
This trial tests if unloading the heart during ECMO support helps patients recover better from cardiogenic shock. It compares different ways to reduce the heart's workload.
This trial tests a new heart pump (Impella device) for people who have a severe heart attack and go into shock (very low blood pressure). It aims to see if the pump can help the heart recover better than standard care.
This study is for people in the intensive care unit who are using a heart pump called Impella. It will collect information about how well the heart pumps blood during treatment to help doctors learn more.
This study examines detailed data from patients who received an Impella 5.5 heart pump to treat cardiogenic shock—a life-threatening condition where the heart cannot pump enough blood. Researchers use advanced computer analysis to understand what helps patients recover best.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.